Text Size

Studying Gene Expression and Location in Samples From Patients With Brain Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01585389
First received: April 24, 2012
Last updated: April 29, 2012
Last verified: April 2012
History of Changes
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to brain tumors.

PURPOSE: This research studies gene expression and location in samples from patients with brain tumors.


Condition Intervention
Brain and Central Nervous System Tumors
 Genetic: gene expression analysis
Genetic: genetic linkage analysis
Genetic: microarray analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: Expression and Subcellular Localization of NEIL3 in Tumors

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Correlation of NEIL3 expression and/or nuclear localization with tumor type or grade with respect to degree of differentiation [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: April 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine the expression and subcellular localization of nei endonuclease VIII-like 3 (NEIL3) in brain tumors.

OUTLINE: Tissue microarray samples are analyzed for NEIL3 expression and subcellular localization by immunohistochemical methods.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Tissue microarrays (TMA) samples from the Biopathology Core

  • Samples from patients diagnosed with brain tumors

    • Progenitor, or blast, cell origin

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01585389

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Principal Investigator: Heithem M. El-Hodiri, PhD Nationwide Children's Hospital
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01585389     History of Changes
Other Study ID Numbers: CDR0000732178, COG-ABTR12B3
Study First Received: April 24, 2012
Last Updated: April 29, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult brain tumor
childhood brain tumor

Additional relevant MeSH terms:
Brain Neoplasms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
 Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 16, 2013